For the quarter ending 2026-03-31, NAMS made $3,040K in revenue. -$49,013K in net income. Net profit margin of -1612.27%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 3,040 | 32 | 348 | 19,145 |
| Research and development expenses | 38,009 | 38,594 | 30,971 | 27,516 |
| Selling, general and administrative expenses | 23,451 | 27,418 | 24,520 | 27,264 |
| Total operating expenses | 61,460 | 66,012 | 55,491 | 54,780 |
| Operating loss | -58,420 | -65,980 | -55,143 | -35,635 |
| Interest income | 5,650 | 6,473 | 6,713 | 7,055 |
| Fair value change - earnout | - | -1 | - | - |
| Fair value change - warrants | -5,942 | 15,335 | 23,792 | -2,590 |
| Loss on disposal of property, plant and equipment | - | - | -1 | - |
| Foreign exchange losss/(gaines) | -1,613 | -82 | 218 | 8,626 |
| Loss before tax | -48,441 | -74,923 | -72,005 | -17,364 |
| Loss for the year | -48,441 | -74,923 | -72,005 | -17,364 |
| Unrealized gain/(loss) on available-for-sale securities, net of tax | -572 | 153 | 313 | -107 |
| Total comprehensive loss for the year, net of tax | -49,013 | -74,770 | -71,692 | -17,471 |
| Basic EPS | -0.4 | -0.623 | -0.61 | -0.15 |
| Diluted EPS | -0.4 | -0.623 | -0.61 | -0.15 |
| Basic Average Shares | 121,716,006 | 120,015,225 | 119,000,266 | 118,556,492 |
| Diluted Average Shares | 121,716,006 | 120,015,225 | 119,000,266 | 118,556,492 |
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)